CompletedNot Applicable

Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone

Saudi Arabia509 participantsStarted 2023-10-01

Plain-language summary

Aldosterone antagonists or mineralocorticoid receptor antagonists (MRAs) are used as therapeutic agents for the management of HF with reduced ejection fraction (HFrEF). Gender-related differences have been described in the regulation of the renin-angiotensin-aldosterone system (RAAS), which is at the core of the pathophysiology of HF. Regarding gender-related differences in the use of MRAs, less is known about the effects of androgens on the RAAS, even though studies have suggested that androgens may increase the RAAS pathway. There are conflicting results because many clinical trials were not specifically designed to investigate gender differences.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult (≥ 18 years) ambulatory patients of both sexes with a diagnosis of HFrEF (LVEF≤ 40%) and NYHA class II-IV under optimized medical therapy who are presented to the outpatient clinic and started spironolactone at the time of enrollment. Exclusion Criteria: * Pregnancy or breastfeeding * Serum creatinine \> 2.5 mg/dL (221 µmol/L) in males and \> 2 mg/dL (177 µmol/L) in women (or estimated glomerular filtration rate (eGFR) ≤ 30 mL/minute/1.73 m2) * Hyperkalemia (serum potassium level \> 5 mEq/L) * Renal transplantation * Concomitant administration of potent CYP3A inhibitors * Concomitant administration of potassium supplements or potassium-sparing diuretics * Disorders of the adrenal glands (such as Addison disease). * Patients who used MRA in the last 2 weeks before enrollment.

What they're measuring

HF Hospitalization

Timeframe: 6 months after enrollment

Trial details

NCT IDNCT06641284

SponsorAhmad Abdullah Salawi

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-10-15